Suggested remit: To appraise the clinical and cost effectiveness of upadacitinib within its marketing authorisation for treating moderately to severely active ulcerative colitis.
 
Status In progress
Technology type Medicine
Decision Selected
Process STA
ID number 3953

Provisional Schedule

Committee meeting: 1 11 October 2022
Expected publication 04 January 2023

Project Team

Project lead Jeremy Powell

Email enquiries

External Assessment Group Centre for Reviews and Dissemination and Centre for Health Economics, University of York

Stakeholders

Companies sponsors AbbVie (upadacitinib)
Others Department of Health and Social Care
  NHS England
  NHS Northern, Eastern and Western Devon CCG
  NHS Windsor, Ascot and Maidenhead CCG
  Welsh Government
Patient carer groups Bladder and Bowel Community
  Bowel Cancer UK
  Colostomy UK
  Crohn’s and Colitis UK
  GUTS UK
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Ulcerative Colitis UK
Professional groups Association of Coloproctology for Great Britain and Ireland
  British Geriatrics Society
  British Society of Gastroenterology
  Neonatal & Paediatric Pharmacist Group
  Primary Care Society for Gastroenterology
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal Society of Medicine
  Royal Pharmaceutical Society
  UK Clinical Pharmacy Association
Comparator companies AbbVie (adalimumab)
  Amgen (adalimumab)
  Biogen Biosimilars (adalimumab, infliximab)
  Bristol-Myers Squibb Pharmaceuticals (ozanimod)
  Celltrion Healthcare UK (adalimumab, infliximab)
  Fresenius Kabi (adalimumab)
  Galapagos Biotech (filgotinib)
  Gilead Sciences (filgotinib)
  Janssen-Cilag (ustekinumab)
  Merck Sharp & Dohme (golimumab, infliximab)
  Pfizer (infliximab, tofacitinib)
  Sandoz (adalimumab, infliximab)
  Takeda UK (vedolizumab)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Scottish Society of Gastroenterology
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Group
  Cochrane UK
  Genomics England
  MRC Clinical Trials Unit
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
23 February 2022 Invitation to participate
23 February 2022 In progress. Final scope issued.
08 November 2021 - 06 December 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual